WO2024085100A1 - Préparation huileuse dispersée de particules solides - Google Patents

Préparation huileuse dispersée de particules solides Download PDF

Info

Publication number
WO2024085100A1
WO2024085100A1 PCT/JP2023/037321 JP2023037321W WO2024085100A1 WO 2024085100 A1 WO2024085100 A1 WO 2024085100A1 JP 2023037321 W JP2023037321 W JP 2023037321W WO 2024085100 A1 WO2024085100 A1 WO 2024085100A1
Authority
WO
WIPO (PCT)
Prior art keywords
oil
solid particle
ophthalmic
surfactant
formulation
Prior art date
Application number
PCT/JP2023/037321
Other languages
English (en)
Japanese (ja)
Inventor
桃子 北岡
航平 石濱
Original Assignee
ＮＯＶＩＧＯ Ｐｈａｒｍａ株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ＮＯＶＩＧＯ Ｐｈａｒｍａ株式会社 filed Critical ＮＯＶＩＧＯ Ｐｈａｒｍａ株式会社
Publication of WO2024085100A1 publication Critical patent/WO2024085100A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Definitions

  • the present disclosure relates to solid particle dispersion oil-based formulations.
  • Formulations for treating ophthalmic diseases are being developed.
  • US2021/145736A, US2017/273901A, US2013/164285A, US2012/258163A, and US2016/0235674A disclose methods for intravitreal administration of drugs.
  • WO2021/049529A, EP3950071A, US2019/117777A, JP2018-70535A, EP2298282A, and US2010/298447A disclose dispersions of particles having a core-shell structure as formulations for transdermal administration.
  • the present disclosure relates to a solid particle dispersion oil formulation.
  • the solid particle dispersion oil formulation includes (i) a solid complex including particles containing a pharma- ceutically acceptable target substance or target molecule (e.g., a nucleic acid or a biopharmaceutical) and a pharma- ceutically acceptable surfactant, and (ii) a pharma- ceutically acceptable oil base.
  • a pharma- ceutically acceptable target substance or target molecule e.g., a nucleic acid or a biopharmaceutical
  • a pharma- ceutically acceptable surfactant e.g., a pharma- ceutically acceptable surfactant
  • a pharma- ceutically acceptable oil base e.g., a pharma- ceutically acceptable oil base.
  • the particles are typically coated with the surfactant.
  • the target substance or target molecule may be water-soluble.
  • the present disclosure also provides a solid particle disper
  • the present disclosure further provides a solid particle dispersion oil formulation for ophthalmic or intraocular administration.
  • an ophthalmic formulation is provided, the formulation including (i) a solid complex including particles containing a pharma- ceutically acceptable target substance or target molecule and a pharma- ceutically acceptable surfactant, and (ii) a pharma- ceutically acceptable oil base.
  • an ophthalmic formulation comprising: (i) a solid complex comprising particles containing a pharma- ceutically acceptable target substance or molecule and a pharma-ceutically acceptable surfactant; and (ii) a pharma-ceutically acceptable oil base.
  • An ophthalmic preparation comprising: (i) a solid complex comprising particles containing a pharma- ceutically acceptable target substance or molecule and a pharma-ceutically acceptable surfactant; (ii) a pharma- ceutically acceptable oil base; the particles are coated with the surfactant, The solid complex is dispersed in the oil base.
  • Ophthalmic preparations (2) The ophthalmic preparation according to (1) above, which is formulated as an eye drop. (3) The ophthalmic preparation according to (1) above, which is for intravitreal administration or is formulated for intravitreal administration.
  • the average hydrodynamic particle size is 80 nm to 200 nm.
  • the oily base is silicone oil.
  • FIG. 1 shows a schematic diagram of a test system simulating the intravitreal environment.
  • FIG. 2A shows the release profile of antibody molecules from a formulation of the present disclosure in a test system simulating the intravitreal environment.
  • FIG. 2B shows particle formation and particle size distribution of the particles formed for a formulation of the present disclosure that includes an antibody as a substance or molecule of interest.
  • FIG. 3A shows the release behavior of a protein molecule (eg, lysozyme) from a formulation of the present disclosure in a test system simulating the intravitreal environment.
  • FIG. 3B shows particle formation and the size distribution of the formed particles in a formulation of the present disclosure that includes a protein molecule (lysozyme) as a target substance or molecule.
  • FIG. 1 shows a schematic diagram of a test system simulating the intravitreal environment.
  • FIG. 2A shows the release profile of antibody molecules from a formulation of the present disclosure in a test system simulating the intravitreal environment.
  • FIG. 4A shows the release profile of an anti-VEGF antibody from a formulation of the present disclosure in a test system simulating the intravitreal environment.
  • FIG. 4B shows the transfer of anti-VEGF antibody from a formulation of the present disclosure to the retina and choroid following ocular administration to rabbits.
  • FIG. 54 shows the vitreous accumulation of anti-VEGF antibodies from a formulation of the present disclosure administered intravitreally to rabbits.
  • FIG. 4D shows the translocation of anti-VEGF antibody from a formulation of the present disclosure to the retina and choroid following intravitreal administration in rabbits.
  • FIG. 5 shows the release profile of aflibercept from a formulation of the present disclosure in a test system simulating the intravitreal environment.
  • FIG. 6 is a histological section (hematoxylin and eosin stained) of the eye of a mouse to which a formulation of the present disclosure was administered intravitreally.
  • a "subject” refers to a mammal, including a human, and preferably a human.
  • mammals include, but are not limited to, humans, chimpanzees, and other primates; dogs, cats, rabbits, horses, sheep, goats, cows, pigs, rats (including nude rats), mice (including nude mice and skid mice), guinea pigs, and other livestock animals, pets, and laboratory animals.
  • a "solid composite” is a composite made of solids.
  • a solid composite may contain water, but is a composite containing solid components.
  • a solid composite may be water-free or have a low water content, for example, a water content of 1% by weight or less, 0.9% by weight or less, 0.8% by weight or less, 0.7% by weight or less, 0.6% by weight or less, 0.5% by weight or less, 0.4% by weight or less, 0.3% by weight or less, 0.2% by weight or less, or 0.1% by weight or less, as measured by a known method (e.g., Karl Fischer method).
  • a solid composite containing hydrophilic molecules and a surfactant may have a core-shell structure, in which the core contains hydrophilic molecules and the shell contains a surfactant, and the surfactant may have a hydrophilic portion facing the core and a hydrophobic portion facing the outer surface of the solid composite.
  • the surfactant preferably covers the surface of the hydrophilic drug and turns the particle surface hydrophobic.
  • a "solid particle-dispersed oil preparation” is a preparation that includes a plurality of solid particles and an oil base, and the solid particles are dispersed in the oil base.
  • the solid particles include a target substance or target molecule (e.g., a nucleic acid or a biopharmaceutical) and a surfactant.
  • the solid particles also contain no water or only a limited amount of water.
  • the particle size is typically less than 1 ⁇ m.
  • the solid particles can be stably dispersed in the oil base.
  • the “solid particle” is also referred to as a "solid complex.”
  • the target substance or target molecule may be hydrophilic, and in this case, the solid particle-dispersed oil preparation is a preparation in which a hydrophilic target substance or target molecule is dispersed in an oil base using a surfactant.
  • the target substance or target molecule may be, for example, a biomolecule.
  • the target substance or target molecule may be, for example, a pharmaceutical active ingredient.
  • the target substance or target molecule may be, for example, a therapeutic drug for an ophthalmic disease.
  • the solid particle dispersion oil preparation preferably does not contain aggregates formed by aggregation of multiple particles (particularly 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, or 10 or more).
  • a biopharmaceutical is a pharmaceutical product that contains an active pharmaceutical ingredient produced by cells.
  • a "surfactant” is a molecule that has a relatively hydrophilic portion and a relatively hydrophobic portion in the molecule.
  • Surfactants are broadly classified into ionic surfactants and nonionic surfactants.
  • Ionic surfactants include cationic surfactants and anionic surfactants.
  • an ionic surfactant may have either a cation or an anion and a hydrophobic portion.
  • a cationic surfactant may contain a cationic portion and a fatty chain (e.g., a long fatty chain) such as an alkyl, alkenyl, or alkynyl.
  • An anionic surfactant may contain an anionic portion and a fatty acid such as a long chain fatty acid, an unsaturated fatty acid (e.g., monovalent or divalent), or a long chain unsaturated fatty acid (e.g., monovalent or divalent).
  • a fatty acid such as a long chain fatty acid, an unsaturated fatty acid (e.g., monovalent or divalent), or a long chain unsaturated fatty acid (e.g., monovalent or divalent).
  • "Long chain” is a term given to compounds that have 14 to 22 carbon atoms.
  • the fatty chain may be a fatty chain with 8 to 22 carbon atoms, i.e., a C 8 to C 22 fatty chain such as a C 8 to C 22 alkyl, C 8 to C 22 alkenyl, or C 8 to C 22 alkynyl.
  • the fatty chain may be a long fatty chain.
  • Saturated means that the fatty chain has no double or triple bonds
  • unsaturated means that the fatty chain has at least one double or triple bond.
  • the fatty chain having a double bond may be a cis type or a trans type, and the cis type is preferred from the viewpoint of biocompatibility.
  • a nonionic surfactant is a surfactant that does not have an ionic group in the molecule, and has a nonionic hydrophilic portion and a hydrophobic portion.
  • the hydrophobic portion may include a fatty chain such as an alkyl, alkenyl, or alkynyl (e.g., a long fatty chain).
  • an ester compound made from unsaturated fatty acids such as erucic acid and oleic acid is preferred.
  • lipophilic nonionic surfactants include sucrose fatty acid esters (sucrose stearate, sucrose palmitate, sucrose myristic acid, sucrose oleate, sucrose laurate, sucrose erucate, sucrose mixed fatty acid esters) with a high degree of esterification (i.e., a high ratio of di-, tri-, and polyester to monoester), polyglycerol condensed ricinoleate, decaglycerol ester, glycerol fatty acid ester, polyglycerol fatty acid ester, polyoxyethylene glycerol fatty acid ester, sorbitan fatty acid ester, polyoxyethylene sorbitol fatty acid ester, and polyoxyethylene castor oil/hydrogenated castor oil.
  • the nonionic surfactant is preferably sucrose laurate.
  • Surfactants include, for example, polyoxyl 40 stearate, polyoxyethylene hydrogenated castor oil 60, polyoxyethylene castor oil, polyoxyethylene (160) polyoxypropylene (30) glycol, polyoxyethylene (200) polyoxypropylene (70) glycol, polysorbate 80, macrogol 4000, macrogol 6000, aluminum monostearate, polyethylene glycol monostearate, glyceryl monostearate, nonoxynol-9, octoxynol-40, polyethylene glycol (PEG)/polypropylene glycol (PPG)-4/30 copolymer, poloxamer 188, poloxamer 407, polyoxyl 15 hydroxystearate, polyoxyl 35 castor oil, polyoxyl 40 hydrogenated castor oil, polyoxyl 40 stearate, and polysorbate 20.
  • polyoxyl 40 stearate polyoxyethylene hydrogenated castor oil 60, polyoxyethylene castor oil, polyoxyethylene (160) polyoxypropylene (30) glycol, polyoxy
  • a suitable example of a surfactant used to prepare the complex is a lipophilic (hydrophobic) nonionic surfactant with an HLB (Hydrophile-Lipophile Balance) value of 10 or less.
  • the HLB of the nonionic surfactant is preferably 8 or less, more preferably 5 or less, and particularly preferably 3 or less.
  • antibody refers to an immunoglobulin.
  • the antibody may be of various isotypes, e.g., IgG.
  • the antibody may preferably be a monoclonal antibody.
  • the antibody may be a human chimeric antibody, a humanized antibody, or a human antibody.
  • a human chimeric antibody may be produced by replacing the constant region of a non-human antibody with the constant region of a human antibody.
  • a humanized antibody may be produced by replacing the six CDRs of a human antibody with the six corresponding CDRs of a non-human antibody.
  • a human antibody may be produced using an animal (e.g., a mouse) in which at least the heavy chain variable region of an immunoglobulin has been replaced with the corresponding region of a human locus.
  • a human antibody can be obtained by replacing the constant region with the amino acid sequence of a human antibody.
  • the antibody may preferably be a humanized antibody.
  • the antibody may preferably be a human antibody.
  • An antibody has a signal peptide when produced intracellularly, but the signal peptide is removed when secreted extracellularly. Therefore, when administered as a pharmaceutical, the antibody does not require a signal peptide.
  • CDR refers to a complementarity determining region present in the heavy and light chain variable regions of an antibody. There are three CDRs in each of the heavy and light chain variable regions, and they are called CDR1, CDR2, and CDR3 from the N-terminus.
  • the CDRs can be determined, for example, based on the numbering scheme of Kabat et al. (Kabat, E. A. et al., Sequences of Proteins of Immunological Interest, 5th ed., 1991, Bethesda: US Dept. of Health and Human Services, PHS, NIH.).
  • antigen-binding fragment of antibody means a fragment of an antibody that maintains binding to an antigen.
  • antigen-binding fragments include Fab, Fab', F(ab') 2 , Fv, scFv (single chain Fv), diabody, and sc(Fv) 2 (single chain (Fv) 2 ).
  • Fab can be obtained by digesting an antibody with papain.
  • F(ab') 2 can be obtained by digesting an antibody with pepsin, and Fab' can be obtained by further reducing this.
  • Antigen-binding fragments of other antibodies can also be prepared by methods well known to those skilled in the art. Such antigen-binding fragments of antibodies can be used in the present invention.
  • pharmaceutical acceptable means that when administered to a subject as a medicine, it does not cause unacceptable toxicity.
  • intraocular administration refers to invasive administration to the eyeball other than eye drops.
  • intraocular administration include intravitreal administration, subconjunctival administration, suprachoroidal administration, and subretinal administration.
  • a solid particle dispersion oil formulation comprising: (i) a solid complex comprising particles containing a pharma- ceutically acceptable target substance or molecule and a pharma-ceutically acceptable surfactant; (ii) a pharma- ceutically acceptable oily base.
  • the solid particle dispersion oil formulation of the present disclosure may be free of water or have a low water content, for example, the water content may be 1% by mass or less, 0.9% by mass or less, 0.8% by mass or less, 0.7% by mass or less, 0.6% by mass or less, 0.5% by mass or less, 0.4% by mass or less, 0.3% by mass or less, 0.2% by mass or less, or 0.1% by mass or less, as measured by known methods.
  • the target substance or target molecule is hydrophilic.
  • the target substance or target molecule can be a physiologically active substance, for example, a biomolecule.
  • the biomolecule is a molecule found in a living organism or an analog thereof, for example, a protein, a peptide, an antibody or an antigen-binding fragment thereof, a nucleic acid, or other biomolecule.
  • the biomolecule may or may not be chemically modified.
  • Ophthalmic solutions are the most widely used non-invasive drug administration form for treating anterior ocular diseases due to their non-invasiveness and convenience.
  • anterior ocular diseases include glaucoma, allergic conjunctivitis, anterior uveitis, and cataracts.
  • hydrophilic active ingredient in eye drops so long as it is a medicinal ingredient that is administered to the eye.
  • the antibody may be, but is not limited to, an antibody that has benefits for absorption through the skin or intraocular (intravitreal) administration.
  • the antibody include, for example, anti-VEGF antibodies (e.g., ranibizumab, bevacizumab, aflibercept, or brolucizumab).
  • Anti-VEGF antibodies have been confirmed to be effective against age-related macular degeneration, diabetic retinopathy (diabetic macular edema), retinal vein occlusion, pathological myopia (choroidal neovascularization), and the like.
  • the antibody or antigen-binding fragment thereof does not lose its antigen-binding ability in a solid complex or in a solid particle-dispersed oil formulation, and exhibits antigen-specific binding after administration.
  • the protein or peptide does not lose its antigen-binding ability in a solid complex or in a solid particle-dispersed oil formulation, and exerts at least a part of its function after administration. Examples of the protein or peptide include lysozyme, insulin, albumin, ovalbumin, neutrophin 4, and the like.
  • the nucleic acid includes one or more selected from the group consisting of DNA, RNA, and modified nucleic acid.
  • the nucleic acid may be a single-stranded or double-stranded nucleic acid.
  • the nucleic acid may be an antisense oligo.
  • the RNA may include artificial RNA for gene silencing, such as siRNA and shRNA, non-coding RNA, such as microRNA (miRNA), aptamers, and natural RNA, such as mRNA.
  • the nucleic acid or RNA may include aptamers (e.g., anti-VEGF aptamers). These RNAs may be modified to be stabilized in vivo.
  • Modified nucleic acids include, for example, nucleic acids modified with fluorescent dyes, biotinylated nucleic acids, and nucleic acids into which cholesteryl groups have been introduced.
  • bases may be modified with 2'-O-methyl, 2'-fluoro, or 2'-methoxyethyl (MOE), and the phosphodiester bonds in the nucleic acid backbone may be replaced with phosphorothioate bonds.
  • Artificial nucleic acids include nucleic acids in which the oxygen atom at the 2' position is crosslinked with the carbon atom at the 4' position.
  • LNA locked nucleic acid
  • ENA in which the oxygen atom at the 2' position and the carbon atom at the 4' position are bridged via ethylene
  • BNACOC in which the oxygen atom at the 2' position and the carbon atom at the 4' position are bridged via -CH 2 OCH 2 -
  • bridged nucleic acid (BNA) such as BNANC, in which the oxygen atom at the 2' position and the carbon atom at the 4' position are bridged via -NR-CH 2 - (where R is a methyl or hydrogen atom);
  • cMOE in which the oxygen atom at the 2' position and the carbon atom at the 4' position are bridged via -CH 2 (OCH 3 ) - ; )-bridged cEt; AmNA in which the 2'- and 4'-carbon
  • surfactant can be used without particular restrictions as long as it is medicamentally acceptable.
  • surfactants include nonionic surfactants, anionic surfactants, cationic surfactants, amphoteric surfactants, and bile salts.
  • Nonionic surfactants include polyglycerol condensed ricinoleate, decaglycerol ester, glycerol fatty acid ester, polyglycerol fatty acid ester, polyoxyethylene glycerol fatty acid ester, sorbitan fatty acid ester, polyoxyethylene sorbitol fatty acid ester, polyoxyethylene castor oil, hydrogenated castor oil, sucrose fatty acid ester (sucrose stearate, sucrose palmitate, sucrose myristate, sucrose oleate, sucrose laurate, sucrose erucate, sucrose mixed fatty acid ester), etc. One of these may be selected for use, or a mixture of two or more may be used.
  • ester compounds made from unsaturated fatty acids such as erucic acid and oleic acid are preferred, and more preferred are sucrose erucic acid ester, sucrose oleic acid ester, and sucrose mixed fatty acid ester.
  • one or more surfactants selected from the group consisting of glycerin fatty acid ester, polyglycerin fatty acid ester, polyoxyethylene glycerin fatty acid ester, sorbitan fatty acid ester, sucrose fatty acid ester, polyoxyethylene sorbit fatty acid ester, polyoxyethylene castor oil, and hydrogenated castor oil can be used.
  • the HLB value indicates the degree of hydrophilicity and hydrophobicity of a surfactant.
  • a smaller HLB value means a higher hydrophobicity.
  • the surfactant is not particularly limited, but it is preferable to use one with high hydrophobicity, with an HLB value of 10 or less. This is because it can easily dissolve or disperse the antigen-containing complex in the oil phase.
  • surfactants having an HLB value of 10 or less, 8 or less, 6 or less, 5 or less, 4 or less, or 3 or less may be preferably used. In the present disclosure, the smaller the HLB value, the more preferable.
  • a water-soluble target substance or molecule When a water-soluble target substance or molecule is mixed with a surfactant in an oil phase (preferably a volatile oil phase), particles having a core-shell structure are formed, the core containing the water-soluble target substance or molecule and the shell containing the surfactant.
  • the particles are dispersed in the oil phase.
  • the oil phase used here is a volatile oil phase (e.g., cyclohexane)
  • it is easy to subsequently evaporate the solvent and by removing the solvent by drying (e.g., freeze-drying)
  • the core-shell particles containing the water-soluble target substance or molecule and the shell containing the surfactant can be obtained as solid particles (also called "solid composites").
  • solid particles also called "solid composites"
  • the solid particles may have an average hydrodynamic particle size of 50 nm to 200 nm as determined by dynamic light scattering. In some embodiments, the average hydrodynamic particle size may be 100 to 160 nm. In some embodiments, the average hydrodynamic particle size may be 80 to 120 nm.
  • the oil base may be any oil that is acceptable for use in pharmaceutical preparations administered to the eye (i.e., ophthalmic preparations such as eye drops or preparations for intravitreal administration).
  • the oil base may be preferably an oil that is liquid at room temperature (25°C).
  • the oil base may be either natural or synthetic.
  • the oil base may be, for example, vegetable oils such as soybean oil, cottonseed oil, rapeseed oil, sesame oil, corn oil, peanut oil, safflower oil, sunflower oil, olive oil, castor oil, rapeseed oil, perilla oil, fennel oil, lanolin, lanolin oil, lanolin alcohol, refined lanolin, mineral oil, cacao oil, cinnamon oil, peppermint oil, eucalyptus oil, and bergamot oil, or animal oils such as beef tallow, lard, and fish oil.
  • vegetable oils such as soybean oil, cottonseed oil, rapeseed oil, sesame oil, corn oil, peanut oil, safflower oil, sunflower oil, olive oil, castor oil, rapeseed oil, perilla oil, fennel oil, lanolin, lanolin oil, lanolin alcohol, refined lanolin, mineral oil, cacao oil, cinnamon oil, peppermint oil, eucalyptus oil, and bergamot oil
  • the oil base may be a neutral lipid such as glyceride, triolein, trilinolein, tripalmitin, tristearin, trimyristin, triarachidonin, or a synthetic lipid.
  • the oil base may be a sterol derivative such as cholesteryl oleate, cholesteryl linoleate, cholesteryl myristate, cholesteryl palmidate, or cholesteryl arachidate, or a long-chain fatty acid ester such as isopropyl myristate, octyldodecyl myristate, cetyl myristate, ethyl oleate, ethyl linoleate, isopropyl linoleate, isopropyl palmitate, or butyl stearate.
  • the oil phase may be a carboxylic acid ester such as ethyl lactate, cetyl lactate, triethyl citrate, diisopropyl adipate, diethyl sebacate, diisopropyl sebacate, or cetyl 2-ethylhexanoate, or a hydrocarbon such as petrolatum, white petrolatum, liquid paraffin, squalane, or vegetable squalane, or a silicone oil.
  • the oil-based base material may be used alone or in a mixture of two or more.
  • Preferred oil-based base materials include squalane oil, castor oil, sesame oil, white petrolatum, and liquid paraffin, and more preferred oil-based base materials include castor oil, isopropyl myristate, and silicone oil.
  • the oil base is castor oil
  • the surfactant can be any one or more surfactants selected from the group consisting of glyceryl dioleate, polyoxyethylene hydrogenated castor oil 10, sorbitan sesquioleate, and sucrose laurate.
  • the solid particle-dispersed oil-based formulation is formulated as an ophthalmic formulation (e.g., eye drops or intraocular formulation).
  • an ophthalmic formulation e.g., eye drops or intraocular formulation
  • a solid complex comprising particles containing a pharma- ceutically acceptable target substance or molecule and a pharma-ceutically acceptable surfactant
  • a pharma- ceutically acceptable oil base is provided.
  • the ophthalmic formulation is an eye drop.
  • the ophthalmic formulation is an intravitreal formulation.
  • the solid particle dispersion oil formulation can release the target substance or target molecule in a sustained manner.
  • the solid particle dispersion oil formulation can release the target substance or target molecule in the eye of a living body (e.g., in the vitreous body) for at least 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 9 hours, 12 hours, 18 hours, 24 hours (2 days), 3 days, 4 days, 5 days, 6 days, 7 days (1 week), or 2 weeks.
  • the solid particle dispersion oil formulation of the present disclosure can release the target substance or target molecule in the ocular irrigation solution for at least 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 9 hours, 12 hours, 18 hours, 24 hours (2 days), 3 days, 4 days, 5 days, 6 days, 7 days (1 week), or 2 weeks.
  • the solid particle dispersion oil formulation releases the target substance or target molecule only at or below the sustained release standard value.
  • the sustained release standard value is a standard time in which the target substance or target molecule contained in the formulation is released at 50% or less, 40% or less, 35% or less, 30% or less, 25% or less, 20% or less, 15% or less, 10% or less, or 5% or less.
  • the sustained release standard time can be, for example, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 9 hours, 12 hours, 18 hours, 24 hours (2 days), 3 days, 4 days, 5 days, 6 days, 7 days (1 week), or 2 weeks.
  • the sustained release preferably occurs after administration to the vitreous of the subject.
  • the solid particle dispersion oil formulation of the present disclosure can deliver the target substance or molecule to one or more of the anterior ocular tissues selected from the group consisting of the cornea, conjunctiva, aqueous humor, iris, ciliary body, and lens, and the posterior ocular tissues selected from the group consisting of the sclera, choroid, retinal pigment epithelium, neural retina, optic nerve, vitreous membrane, and vitreous humor.
  • the solid particle dispersion oil formulation of the present disclosure can deliver the target substance or molecule to one or more of the above tissues over an extended period of time.
  • the eye drops of the present disclosure are dispersed in an oily base and are less likely to be excreted by tears than hydrophilic substances.
  • the eye drops of the present disclosure may also pass through the corneal epithelium, which exhibits hydrophobic properties, and may be suitable for the penetration of drugs into ocular tissues and posterior ocular tissues.
  • the eye drops of the present disclosure may have tissue permeability.
  • the formulation for intravitreal administration of the present disclosure is dispersed in an oily base and is less likely to be diffused or excreted by vitreous humor than hydrophilic substances. It is believed that the form of the solid particle-dispersed oily formulation may inhibit the active ingredient from diffusing prematurely into body fluids, allowing the active ingredient to be released gradually.
  • a method of treating an ophthalmic disease in a subject includes administering to the subject a therapeutic agent for ophthalmic disease of the present disclosure.
  • the therapeutic agent for ophthalmic disease may be a solid particle dispersion oily formulation containing the therapeutic agent for ophthalmic disease as a drug.
  • the administration may be by eye drops or intraocular administration, preferably intravitreal administration.
  • the amount administered may be a therapeutically effective amount.
  • the present disclosure provides a method for administering a therapeutic drug for ophthalmic disease to a subject, the therapeutic drug for ophthalmic disease being a solid particle dispersion oil formulation containing the therapeutic drug for ophthalmic disease as a drug.
  • a solid particle dispersion oil formulation for use in the method of the present disclosure.
  • a solid particle dispersion oil formulation or a target substance or target molecule in the manufacture of a medicament for use in the method of the present disclosure.
  • Example 1 Preparation of eye drop preparation and intravitreal preparation
  • a preparation in which solid particles formed by coating a drug with a surfactant are dispersed in oil was applied to the eye.
  • Drugs used included those from a variety of pharmaceutical modalities, including proteins, antibodies, and nucleic acids.
  • An experimental system was constructed to examine the application of solid particle dispersion oil preparations as ophthalmic preparations. Specifically, a stationary jacketed Franz diffusion cell for membrane permeation tests (manufactured by Cosmedy) was divided into the top and bottom by a polycarbonate membrane (pore size: 0.1 ⁇ m, manufactured by Merck), the solid particle dispersion oil preparation was added to the top, and the bottom was filled with ocular irrigation fluid (Opeguard) MA ocular irrigation fluid, manufactured by Senju Pharmaceutical Co., Ltd.). The temperature was maintained at 36°C, which is the eyeball surface temperature. When the obtained solid particle dispersion oil preparation was added to the top, the transfer of the drug to the ocular irrigation fluid in the bottom was confirmed.
  • ocular irrigation fluid Opeguard
  • Antibody A human total IgG antibody was used as the antibody.
  • An aqueous solution containing 1 mg/mL IgG and 0.3 mg mannitol was mixed with a cyclohexane solution containing 25 mg/mL surfactant, and the mixture was stirred for 2 minutes at 26,000 rpm using a homogenizer.
  • the surfactant one selected from glyceryl dioleate (DGMO), sorbitan sesquioleate (SO), polyoxyethylene hydrogenated castor oil 10 (HCO), and sucrose laurate (L195) was used.
  • DGMO glyceryl dioleate
  • SO sorbitan sesquioleate
  • HCO polyoxyethylene hydrogenated castor oil 10
  • sucrose laurate L195
  • the obtained solid particles were dispersed in 1 mL castor oil (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) to obtain a solid particle dispersion oil formulation containing an IgG antibody.
  • the particle size distribution of the solid particles in the obtained solid particle dispersion oil formulation was measured using a Zetasizer (Zetasizer Nano ZS, manufactured by Marvern). The particle size distribution results were as shown in FIG. 2B.
  • the average hydrodynamic particle size was about 110 to 170 nm.
  • the average hydrodynamic particle size of particles with HCO as the surfactant was 120 ⁇ 9 nm, with a PDI of 0.564 to 0.787
  • the average hydrodynamic particle size of particles with DGMO as the surfactant was 114 ⁇ 7 nm, with a PDI of 0.307 to 0.399
  • the average hydrodynamic particle size of particles with SO as the surfactant was 122 ⁇ 12 nm, with a PDI of 0.345 to 0.693
  • the average hydrodynamic particle size of particles with L195 as the surfactant was 163 ⁇ 8 nm, with a PDI of 0.604 to 0.816.
  • the obtained solid particles were dispersed in 1 mL castor oil (manufactured by Fujifilm Wako Pure Chemical Industries, Ltd.) to obtain a solid particle dispersion oil formulation containing lysozyme as an active ingredient.
  • the particle size distribution of the solid particles in the obtained solid particle dispersion oil formulation was measured with a Zetasizer (Zetasizer Nano ZS, manufactured by Marvern). The particle size distribution results are shown in FIG. 3B.
  • Anti-VEGF antibody A commercially available mouse-derived anti-VEGF antibody (Recombinant Mouse VEGF 164 ) was used as the antibody. 100 ⁇ g of a commercially available antibody lyophilized with trehalose and PBS was dissolved in 500 ⁇ L of Milli-Q water. 50 ⁇ L of an aqueous antibody solution was mixed with 2 mL of a cyclohexane solution containing 4 mg/mL surfactant, and stirred for 2 minutes at 26,000 rpm with a homogenizer. The resulting emulsion was lyophilized for 24 hours to remove the solvent, and solid particles in which the drug was coated with the surfactant were obtained.
  • the resulting solid particles were dispersed in 50 ⁇ L of castor oil to obtain a solid particle-dispersed oil formulation containing an anti-VEGF antibody as an active ingredient.
  • the particle size distribution of the solid particles in the resulting solid particle-dispersed oil formulation was measured with a Zetasizer (Zetasizer Nano ZS, manufactured by Marvern). The particle size distribution results were as shown in FIG. 4A.
  • the kinetics of the drug after administration was confirmed using rabbits.
  • the obtained solid particle dispersion oil formulation was administered by eye drop or intravitreally to rabbits so that the antibody amount was 0.4 ⁇ g per single eye.
  • the aqueous humor, vitreous body, and retina/choroid of the rabbits were collected 24 hours, 72 hours, and 120 hours after administration, and the amount of antibody contained in each was measured.
  • Figure 4B after the obtained solid particle dispersion oil formulation was administered by eye drop, some of the anti-VEGF antibodies were detected in the retina/choroid up to 120 hours after administration.
  • Figures 4C and 4D after the obtained solid particle dispersion oil formulation was administered intravitreally, most of the antibodies migrated to the retina/choroid and maintained their concentration for a long period of time.
  • the antibody used was aflibercept, an anti-VEGF antibody.
  • Aflibercept was purified. Specifically, the product additives of Eylea (registered trademark) intravitreal injection solution were removed using PD-10 (Cytiva) according to the manufacturer's manual, and then mannitol was added to the obtained antibody to a final concentration of 0.1%, and Milli-Q water was added to the obtained antibody to an antibody concentration of 1 mg/mL to obtain an antibody aqueous solution. The antibody aqueous solution was mixed with a cyclohexane solution containing 25 mg/mL surfactant, and stirred at 26,000 rpm for 2 minutes using a homogenizer.
  • the obtained emulsion was freeze-dried for 24 hours to remove the solvent, and solid particles in which the drug was coated with the surfactant were obtained.
  • the obtained solid particles were dispersed in 1 mL of isopropyl myristate (manufactured by Tokyo Chemical Industry Co., Ltd.) to obtain a solid particle dispersion oil formulation containing an anti-VEGF antibody as an active ingredient.
  • Example 2 Toxicity Test Mice were used in the test. Mice (Balb/cJJcl, 10 weeks old, female) were intravitreally injected with 100 ⁇ L of solid particle dispersion oil formulation (see STAR Protocols 1, 100094, September 18, 2020), and the eyeballs were collected after 2 weeks and tissue sections were observed under a microscope. The tissue sections were 20 ⁇ m thick and were subjected to hematoxylin-eosin staining. The toxicity of any of the oil bases, castor oil, isopropyl myristate, or silicone oil (KF96), was evaluated.
  • KF96 silicone oil
  • the solid particle-dispersed oil formulation was administered by eye drop and intravitreal administration.
  • the solid particle-dispersed oil formulation was excellent in long-term sustained release performance of the drug when administered by eye drop and intravitreal administration.
  • the solid particle-dispersed oil formulation also had advantages such as high delivery and/or accumulation of the drug to the retina/choroid. It is suggested that the preparation in which solid particles are dispersed in oil (solid particle-dispersed oil formulation) has high tissue permeability and is effective not only in intravitreal administration but also in various intraocular administrations.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente divulgation concerne une préparation huileuse dispersée de particules solides. La présente divulgation concerne également une préparation huileuse dispersée de particules solides appropriée pour des gouttes oculaires ou une administration intraoculaire. La préparation d'huile dispersée de particules solides contient (i) des complexes solides qui contiennent un tensioactif pharmaceutiquement acceptable et des particules contenant une substance cible pharmaceutiquement acceptable ou une molécule cible et (ii) une base huileuse pharmaceutiquement acceptable. Les particules dans la préparation huileuse dispersée de particules solides sont typiquement enrobées avec le tensioactif. De plus, la substance cible ou la molécule cible dans la préparation huileuse dispersée de particules solides peut être soluble dans l'eau.
PCT/JP2023/037321 2022-10-17 2023-10-16 Préparation huileuse dispersée de particules solides WO2024085100A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022-166209 2022-10-17
JP2022166209 2022-10-17

Publications (1)

Publication Number Publication Date
WO2024085100A1 true WO2024085100A1 (fr) 2024-04-25

Family

ID=90737568

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2023/037321 WO2024085100A1 (fr) 2022-10-17 2023-10-16 Préparation huileuse dispersée de particules solides

Country Status (1)

Country Link
WO (1) WO2024085100A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011004552A1 (fr) * 2009-07-09 2011-01-13 国立大学法人九州大学 Support de médicament soluble dans l'eau et son procédé de fabrication
WO2020203809A1 (fr) * 2019-03-29 2020-10-08 日産化学株式会社 Nouveau procédé de production de formulation s/o de lécithine, et formulation associée
WO2022196748A1 (fr) * 2021-03-17 2022-09-22 国立大学法人九州大学 Agent d'absorption transdermique
WO2022264184A1 (fr) * 2021-06-17 2022-12-22 The University Of Jordan Composition ophtalmique en nano-dispersion, procédé pour sa préparation, et formulation de guérison de plaies épithéliales de la cornée

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011004552A1 (fr) * 2009-07-09 2011-01-13 国立大学法人九州大学 Support de médicament soluble dans l'eau et son procédé de fabrication
WO2020203809A1 (fr) * 2019-03-29 2020-10-08 日産化学株式会社 Nouveau procédé de production de formulation s/o de lécithine, et formulation associée
WO2022196748A1 (fr) * 2021-03-17 2022-09-22 国立大学法人九州大学 Agent d'absorption transdermique
WO2022264184A1 (fr) * 2021-06-17 2022-12-22 The University Of Jordan Composition ophtalmique en nano-dispersion, procédé pour sa préparation, et formulation de guérison de plaies épithéliales de la cornée

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JABER MAI; JABER BAHAA; HAMED SAJA; ALKHATIB HATIM S.: "Preparation and evaluation of ascorbyl glucoside and ascorbic acid solid in oil nanodispersions for corneal epithelial wound healing", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, NL, vol. 627, 23 September 2022 (2022-09-23), NL , XP087200549, ISSN: 0378-5173, DOI: 10.1016/j.ijpharm.2022.122227 *
SRIVIDYA GORANTLA: "Nanocarriers for ocular drug delivery: current status and translational opportunity", RSC ADVANCES, ROYAL SOCIETY OF CHEMISTRY, GB, vol. 10, no. 46, 24 July 2020 (2020-07-24), GB , pages 27835 - 27855, XP093161045, ISSN: 2046-2069, DOI: 10.1039/D0RA04971A *

Similar Documents

Publication Publication Date Title
Souto et al. Advanced formulation approaches for ocular drug delivery: state-of-the-art and recent patents
Souza et al. Topical delivery of ocular therapeutics: carrier systems and physical methods
Li et al. Nanoparticulate drug delivery to the retina
Soni et al. Design and evaluation of ophthalmic delivery formulations
Liu et al. Highly bioactive, bevacizumab-loaded, sustained-release PLGA/PCADK microspheres for intravitreal therapy in ocular diseases
UA111168C2 (uk) Емульсія типу вода-в-олії для лікування хвороб ока
Desai et al. Ophthalmic and otic drug administration: novel approaches and challenges
Formica et al. Triamcinolone acetonide-loaded lipid nanocapsules for ophthalmic applications
CA2809460C (fr) Emulsion de type eau-dans-l'huile destinee au traitement d'une maladie oculaire
JP2009538880A (ja) 硝子体内注入用のプロドラッグ
JP7079250B2 (ja) リポソーム構築物を用いた黄斑細胞及び網膜細胞への尿素の送達
JP2011522792A (ja) 生物活性薬の封入
Kim et al. Intraocular distribution and kinetics of intravitreally injected antibodies and nanoparticles in rabbit eyes
US20240207195A1 (en) Ocular drug delivery
JP5920928B2 (ja) 局所眼科用ペプチド製剤
Eriksen et al. Multifarious biologic loaded liposomes that stimulate the mammalian target of rapamycin signaling pathway show retina neuroprotection after retina damage
Chaw et al. In vivo fate of liposomes after subconjunctival ocular delivery
Pignatello et al. Nanotechnology in ophthalmic drug delivery: a survey of recent developments and patenting activity
WO2024085100A1 (fr) Préparation huileuse dispersée de particules solides
Yordanova Andonova A new direction in ophthalmic development: Nanoparticle drug delivery systems
CN109906075A (zh) 用于在发炎病灶或区域中局部注射的脂质体皮质类固醇
US20120058187A1 (en) Water-in-oil type emulsion for treating a disease of the eye
JP2011519893A (ja) 生物活性薬の封入
JP2023541372A (ja) 神経保護方法及びその使用
Kim et al. Ocular permeation enhancers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23879743

Country of ref document: EP

Kind code of ref document: A1